Evidence map›Paper›PMID 40116940›Full record

ArticleCellular and molecular life sciences : CMLS2025

Nicotinamide metabolism reprogramming drives reversible senescence of glioblastoma cells.

Ashwin Narayanan, Mirca S Saurty-Seerunghen, Jessica Michieletto, Virgile Delaunay, Arnaud Bruneel, Thierry Dupré, Chris Ottolenghi, Clément Pontoizeau, Lucrezia Ciccone, Andreas De La Vara and 6 more

Abstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ashwin Narayanan *Sorbonne Université, CNRS, INSERM, Institut de Biologie Paris Seine, Center for Neuroscience at Sorbonne Université, 7 Quai Saint-Bernard, 75005, Paris, France.
Mirca S Saurty-Seerunghen *Sorbonne Université, CNRS, INSERM, Institut de Biologie Paris Seine, Center for Neuroscience at Sorbonne Université, 7 Quai Saint-Bernard, 75005, Paris, France.
Jessica MichielettoSorbonne Université, CNRS, INSERM, Institut de Biologie Paris Seine, Center for Neuroscience at Sorbonne Université, 7 Quai Saint-Bernard, 75005, Paris, France.
Virgile DelaunaySorbonne Université, CNRS, INSERM, Institut de Biologie Paris Seine, Center for Neuroscience at Sorbonne Université, 7 Quai Saint-Bernard, 75005, Paris, France.
Arnaud BruneelService de Biochimie Métabolique et Cellulaire, Hôpital Bichat-Claude-Bernard, Paris, France.
Thierry DupréService de Biochimie Métabolique et Cellulaire, Hôpital Bichat-Claude-Bernard, Paris, France.
Chris OttolenghiFrance Paris Cité University, Imagine Institute -Inserm U1163, Metabolic Biochemistry Laboratory, Necker Hospital (APHP), Paris, France.
Clément PontoizeauFrance Paris Cité University, Imagine Institute -Inserm U1163, Metabolic Biochemistry Laboratory, Necker Hospital (APHP), Paris, France.
Lucrezia CicconeSorbonne Université, CNRS, INSERM, Institut de Biologie Paris Seine, Center for Neuroscience at Sorbonne Université, 7 Quai Saint-Bernard, 75005, Paris, France.
Andreas De La VaraSorbonne Université, CNRS, INSERM, Institut de Biologie Paris Seine, Center for Neuroscience at Sorbonne Université, 7 Quai Saint-Bernard, 75005, Paris, France.
Ahmed IdbaihSorbonne Université, AP-HP, Institut du Cerveau -Paris Brain Institute - ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, DMU Neurosciences, Service de Neuro-Oncologie-Institut de Neurologie, F-75013, Paris, France.
Laurent TurchiCôte D'Azur, CNRS, INSERM, Institut de Biologie Valrose, Team INSERM "Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity", 06108, Nice, France.
Thierry VirolleCôte D'Azur, CNRS, INSERM, Institut de Biologie Valrose, Team INSERM "Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity", 06108, Nice, France.
Hervé ChneiweissSorbonne Université, CNRS, INSERM, Institut de Biologie Paris Seine, Center for Neuroscience at Sorbonne Université, 7 Quai Saint-Bernard, 75005, Paris, France.
Marie-Pierre Junier *Sorbonne Université, CNRS, INSERM, Institut de Biologie Paris Seine, Center for Neuroscience at Sorbonne Université, 7 Quai Saint-Bernard, 75005, Paris, France.
Elias A El-Habr *Sorbonne Université, CNRS, INSERM, Institut de Biologie Paris Seine, Center for Neuroscience at Sorbonne Université, 7 Quai Saint-Bernard, 75005, Paris, France. elias.el-habr@sorbonne-universite.fr.ORCID http://orcid.org/0000-0002-4531-9707

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies show that metabolites, beyond their metabolic roles, can induce significant changes in cell behavior. Herein, we investigate the non-canonical role of nicotinamide (vitamin B3) on glioblastoma (GB) cell behavior. Nicotinamide induced senescence in GB cells, characterized by reduced proliferation, chromatin reorganization, increased DNA damage, enhanced beta-galactosidase activity, and decreased Lamin B1 expression. Nicotinamide-induced senescence was accompanied by an unexpected reprogramming of its metabolism, marked by simultaneous downregulated transcription of NNMT (nicotinamide N-methyltransferase) and NAMPT (nicotinamide phosphoribosyl-transferase). Nicotinamide effects on GB cells were mediated by decreased levels of SOX2. Consistently, analyses of patients' single cell transcriptome datasets showed that GB cells with low NNMT and NAMPT expression levels were enriched in gene modules related to senescence. Remarkably, senescent GB cells retained tumor-forming ability in vivo, albeit to a lesser extent compared to control cells. Further experiments at the single-cell level and transcriptomic analyses demonstrated that nicotinamide-induced senescence in GB cells is fully reversible. Overall, our findings identify a novel reversible senescent state in GB tumors and highlight the non-canonical role of nicotinamide as a key driver of cancer cell plasticity.

Indexed as

Brain NeoplasmsCellular SenescenceGlioblastomaNiacinamideAnimalsCell Line, TumorCell ProliferationCytokinesGene Expression Regulation, NeoplasticHumansMetabolic ReprogrammingMiceNicotinamide N-MethyltransferaseNicotinamide PhosphoribosyltransferaseSOXB1 Transcription FactorsTranscriptomeCytokinesNiacinamideNicotinamide N-MethyltransferaseNicotinamide Phosphoribosyltransferasenicotinamide phosphoribosyltransferase, humanNNMT protein, humanSOX2 protein, humanSOXB1 Transcription FactorsCD44H3K14acH3K27me3Sc-RNAseq

Identifiers

PMID40116940
PMCPMC11928343

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.